Chronic Urticaria clinical trials

Explore recruiting chronic urticaria clinical trials.

Recruiting chronic urticaria studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Urticaria trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants from Jasper-Sponsored Chronic Urticaria Trials

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Parallel Group, Multicentre Study to Compare Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, immunogenicity, of BP11 versus EU-Approved Xolair in patients With Chronic Spontaneous Urticaria Who Are Resistant to H1 Antagonist.

Hungary, Latvia, Bulgaria, Slovakia, Poland, Lithuania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Proof of concept study to assess the efficacy and safety of Danicopan (factor D inhibitor) in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment (DANICSU).

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A 12-week randomized, participant and investigator blinded, placebo-controlled, exploratory study in adult participants with Chronic Urticaria to assess the efficacy and safety and explore the Mechanism of Action of remibrutinib (LOU064)

Poland, France, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria

Germany, Denmark, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines

Romania, Slovakia, Poland, Portugal, France, Hungary +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Chronic Urticaria trials by city

Chronic Urticaria in Toronto Chronic Urticaria in Vancouver Chronic Urticaria in Montreal Chronic Urticaria in Calgary Chronic Urticaria in Edmonton Chronic Urticaria in Ottawa Chronic Urticaria in Winnipeg Chronic Urticaria in Quebec City Chronic Urticaria in Hamilton Chronic Urticaria in Kitchener Chronic Urticaria in London Chronic Urticaria in Halifax Chronic Urticaria in New York Chronic Urticaria in Los Angeles Chronic Urticaria in Chicago Chronic Urticaria in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease